Table 4.
Potency of A/bhg/Ql/1A/05 reference antigen and vaccine using homologous (S‐112) and two heterologous (S‐APS1 and S7854) sera
| Antiserum* | Reference antigen #63 69 μg/ml Starting concentration | Potency of A/bhg vaccine and reference antigen | ||
|---|---|---|---|---|
| A/bhg S‐112 | 69 μg/ml – undiluted | A/bhg Vaccine | #63 A/bhg Ref Antigen† | Replicate/assigned (%)‡ |
| Average (n = 16) | 119·4 | 77·6 | 113 | |
| SD§ | 4·4 | 4·2 | ||
| A/Viet S‐APS1 | 69 μg/ml – undiluted | A/bhg Vaccine | #63 A/bhg | |
| Average (n = 16) | 119·7 | 73·0 | 106 | |
| SD | 3·8 | 4·5 | ||
| A/Indo S‐7854 | 69 μg/ml – undiluted | A/bhg Vaccine | #63 A/bhg | |
| Average (n = 16) | 118·5 | 64·8 | 94 | |
| SD | 5·2 | 4·8 | ||
*Potency antiserum used at 10 μl/ml per single radial immunodiffusion gel.
†Replicate sample of A/bhg reference antigen run and calculated as unknown and compared to assigned potency value of 69 μg/ml.
‡Value of reference antigen determined versus assigned HA concentration.
§SD – standard deviation.